The effect of tripeptide tyroserleutide (YSL) on animal models of hepatocarcinoma

Peptides

Volumn 27, Issue 6, 2006, Pages 1167-1172

  Yao, Zhi ^a,b   Lu, Rong ^a,c   Jia, Jing ^a   Zhao, Pengpeng ^a   Yang, Jing ^a   Zheng, Minna ^a   Lu, Jing ^a   Jin, Mengjue ^a   Yang, Haixian ^a   Gao, Wenyuan ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN UNIVERSITY   (China)

^c Shenzhen Kangzhe Pharmaceutical Co Ltd   (China)

Author keywords

Antitumor; Apoptosis; H22 model; Hepatocarcinoma Bel 7402; Nude mice; Tyroserleutide (tyrosyl seryl leucine, YSL)

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; TRIPEPTIDE; TYROSERLEUTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASCITES FLUID; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; ELECTRON MICROSCOPY; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR CELL;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, CHEMICAL; NECROSIS; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES;

ANIMALIA; MUS MUSCULUS;

EID: 33646798386     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2005.02.026     Document Type: Article

References (24)

1. Cancer facts and figures, The American Cancer Society's Publication (2004), American Cancer Society, Inc., USA
2. Chen R., Zhu D., and Ye X. The establishment and character of human hepacarcimoma cell line BEL-7402 in vitro. Commun Sci 20 9 (1975) 434-436
3. Chene P., Fuchs J., Bohn J., Garcia-Echeverria C., Furet P., and Fabbro D. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J Mol Biol 299 1 (2000) 245-253
4. Ferlay J., Bray F., and Pisani P. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0, IARC CancerBase, No. 5 (2001), IARC Press, Lyon, USA
5. Fujisawa N., Sakao Y., Hayashi S., Hadden W.A., Harmon C.L., and Miller E.J. Alpha-chemokine growth factors for adenocarcinomas; a synthetic peptide inhibitor for alpha-chemokines inhibits the growth of adenocarcinoma cell lines. J Cancer Res Clin Oncol 126 1 (2000) 19-26
6. Guilbaud N., Kraus-Berthier L., Meyer-Losic F., Malivet V., Chacun C., Jan M., et al. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. Clin Cancer Res 7 8 (2001) 2573-2580
7. Hanyue. Research and development of anticancer drugs and experimental techniques. 1st ed. (1997), Peking University Health Center and Peking Union Medical College Publishing House p. 299
8. Hisatsune K., Nozaki S., Ishikawa T., Hayashi M., Nogaki K., and Ogawa H. A biochemical study of the phagocytic activities of tuftsin and its analogues. Ann NY Acad Sci 419 (1983) 205-213
9. Issaeva N., Friedler A., Bozko P., Wiman K.G., Fersht A.R., and Selivanova G. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA 100 23 (2003) 13303-13307 [Epub October 31, 2003]
10. Matsuzaki A., Suminoe A., Hattori H., Hoshina T., and Hara T. Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J Pediatr Hematol Oncol 24 3 (2002) 220-223
11. McDonnell T.J., Meyn R.E., and Robertson L.E. Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol 6 1 (1995) 53-60
12. Najjar V.A., Linehan L., and Konopinska D. The antineoplastic effects of tuftsin and tuftsinyltuftsin on B16/5B melanoma and L1210 cells. Ann NY Acad Sci 419 (1983) 261-267
13. Papo N., and Shai Y. New lytic peptides based on the d,l-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 42 31 (2003) 9346-9354
14. Pawlikowski M., and Melen-Mucha G. Perspectives of new potential therapeutic applications of somatostatin analogs. Neuro Endocrinol Lett 24 1/2 (2003) 21-27
15. Shimosato Y., Kameya T., Nagai K., Hirohashi S., Koide T., Hayashi H., et al. Transplantation of human tumors in nude mice. J Natl Cancer Inst 56 (1976) 1251-1260
16. Xu S., Bian R., and Chen X. Methodology of pharmacological experiment. 3rd ed. (2002), People's Health Publishing House p. 1785-86
17. Tang Z.Y. Small hepatocellular carcinoma: current status and prospects. Hepatobiliary Pancreat Dis Int 1 3 (2002) 349-353
18. Teramoto K., Kontani K., Ozaki Y., Sawai S., Tezuka N., Nagata T., et al. Deoxyribonucleic acid DNA encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy. Cancer Res 63 22 (2003) 7920-7925
19. The guidance for the pre-clinical researches of new drugs western medicine vol. 7 (1993), Pharmic Political Bureau of Ministry of Health, People's Republic of China p. 137-99
20. Wang C., Ding W., Zhao M., Lin Q., and Peng S. Studies on the large scale synthesis and anti-tumor activity of YSL. Prep Biochem Biotechnol 33 3 (2003) 189-195
21. Wang J.F., Ling M.Y., and Chu H.Y. The establishment and biological character of ascitic fluid type liver cancer (H22-Fo/L) in mice. J Pathol China 20 1 (1991) 65
22. Warren P., Li L., Song W., Holle E., Wei Y., Wagner T., et al. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two gamma-linked glutamate residues at the COOH terminus. Cancer Res 61 18 (2001) 6783-6787
23. Yang Y.X., Zhu L., He X., Bao D.Y., and Bao X. Antitumor activity of mitoxantrone-nanosphere against murine liver tumor H22. Sichuan Da Xue Xue Bao Yi Xue Ban (J Sichuan Univ Med Ed) 35 1 (2004) 68-70 [in Chinese]
24. Zhai Y., and Lu Z.J. Effect of thalidomide on tumor growth in mouse hepatoma H22 model. Ai Zheng (Cancer) 22 12 (2003) 1301-1306 [in Chinese]